Rapid Progression of Cataract to Mature Stage After Intravitreal Dexamethasone Implant Injection: a Case Report

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2019 Jan 5

PMID 30606142

Citations 2

Authors

Jae Hyung Lee

Jae Yong Park

Jae Suk Kim

Je Hyung Hwang

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to report a case of rapid progression of cataract to mature stage after intravitreal dexamethasone implantation for macular edema due to branch retinal vein occlusion.

Case Presentation: A 59-year-old Korean male with complaints of sudden metamorphopsia and reduced visual acuity for three days in the left eye was referred to our clinic. Ophthalmological investigations included fundus photography, fluorescein angiography, and optical coherence tomography. In the left eye, branch retinal vein occlusion with macular edema was observed. We performed intravitreal dexamethasone implantation in the left eye three times within a period of one year. One week after the third intravitreal dexamethasone implantation, grade 1 posterior subcapsular opacity and raised intraocular pressure were observed in the left eye. Three weeks later, mature cataract was observed in the left eye. We performed cataract surgery along with intravitreal ranibizumab injection in the left eye. The procedure was uneventful, and the visual acuity improved postoperatively.

Conclusions: Posterior subcapsular cataract developed due to intravitreal dexamethasone implantation can progress rapidly to mature stage. Therefore, short-term follow-up examinations may be necessary for early diagnosis and treatment of this complication.

Citing Articles

Evaluation of a modified sutureless technique for scleral fixation of one-piece posterior chamber intraocular lens: a retrospective study.

Johari M, Attar A, Eghtedari D, Razavizadegan S Front Med (Lausanne). 2025; 11:1503394.

PMID: 39871842 PMC: 11769996. DOI: 10.3389/fmed.2024.1503394.

Safety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study.

Doganay S, Ucan Gunduz G, Kiristioglu M, Demirel E, Yalcinbayir O Eye (Lond). 2025; 39(3):586-592.

PMID: 39774295 PMC: 11794867. DOI: 10.1038/s41433-024-03570-8.

Paclitaxel and Urolithin A Prevent Histamine-Induced Neurovascular Breakdown Alike, in an Rat Eye Model.

Uppada S, Zou D, Scott E, Ko G, Pflugfelder S, Kumar M ACS Chem Neurosci. 2022; 13(14):2092-2098.

PMID: 35574761 PMC: 9928511. DOI: 10.1021/acschemneuro.1c00692.

References

Williamson T, ODonnell A . Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol. 2005; 139(5):860-6. DOI: 10.1016/j.ajo.2005.01.001. View

Jonas J . Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006; 38(4):218-45. DOI: 10.1159/000093796. View

rehak J, Rehak M . Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008; 33(2):111-31. PMC: 2430176. DOI: 10.1080/02713680701851902. View

Campochiaro P, Hafiz G, Shah S, Nguyen Q, Ying H, Do D . Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008; 16(4):791-9. DOI: 10.1038/mt.2008.10. View

Petersen A, Carlsson T, Karlsson J, Jonhede S, Zetterberg M . Effects of dexamethasone on human lens epithelial cells in culture. Mol Vis. 2008; 14:1344-52. PMC: 2480483. View

Yau J, Lee P, Wong T, Best J, Jenkins A . Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 2009; 38(12):904-10. DOI: 10.1111/j.1445-5994.2008.01720.x. View

Ip M, Scott I, VanVeldhuisen P, Oden N, Blodi B, Fisher M . A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein.... Arch Ophthalmol. 2009; 127(9):1101-14. PMC: 2872173. DOI: 10.1001/archophthalmol.2009.234. View

Scott I, Ip M, VanVeldhuisen P, Oden N, Blodi B, Fisher M . A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein.... Arch Ophthalmol. 2009; 127(9):1115-28. PMC: 2806600. DOI: 10.1001/archophthalmol.2009.233. View

Haller J, Bandello F, Belfort Jr R, Blumenkranz M, Gillies M, Heier J . Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010; 117(6):1134-1146.e3. DOI: 10.1016/j.ophtha.2010.03.032. View

10.

Chang-Lin J, Attar M, Acheampong A, Robinson M, Whitcup S, Kuppermann B . Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2010; 52(1):80-6. DOI: 10.1167/iovs.10-5285. View

11.

Thakur A, Kadam R, Kompella U . Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011; 129(7):914-20. PMC: 3407594. DOI: 10.1001/archophthalmol.2011.39. View

12.

Haller J, Bandello F, Belfort Jr R, Blumenkranz M, Gillies M, Heier J . Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011; 118(12):2453-60. DOI: 10.1016/j.ophtha.2011.05.014. View

13.

Haghjou N, Soheilian M, Abdekhodaie M . Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2012; 6(4):317-29. PMC: 3306122. View

14.

Querques L, Querques G, Lattanzio R, Gigante S, Del Turco C, Corradetti G . Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica. 2012; 229(1):21-5. DOI: 10.1159/000342160. View

15.

Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A . Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond). 2012; 27(1):65-71. PMC: 3545388. DOI: 10.1038/eye.2012.226. View

16.

Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V . Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013; 97(8):1040-4. DOI: 10.1136/bjophthalmol-2013-303207. View

17.

Coscas G, Augustin A, Bandello F, Smet M, Lanzetta P, Staurenghi G . Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol. 2013; 24(1):1-9. DOI: 10.5301/ejo.5000376. View

18.

Boyer D, Yoon Y, Belfort Jr R, Bandello F, Maturi R, Augustin A . Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121(10):1904-14. DOI: 10.1016/j.ophtha.2014.04.024. View

19.

Reid G, Sahota D, Sarhan M . OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS. Retina. 2015; 35(8):1647-55. DOI: 10.1097/IAE.0000000000000524. View

20.

Antonetti D, Barber A, Khin S, Lieth E, Tarbell J, Gardner T . Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998; 47(12):1953-9. DOI: 10.2337/diabetes.47.12.1953. View